# Limited Competition for the Continuation of the Rare and Atypical Diabetes NeTwork (RADIANT) Specialized Study Centers (U54 - Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-dk-22-511-limited-competition-for-the-continuation-of-the-rare/  
Official notice: https://www.grants.gov/search-results-detail/345848

> National Institutes of Health offered grants to the applicants described in the notice. Applications closed on June 7, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-DK-22-511 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | June 7, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.847 |

## Who can apply

- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

This Funding Opportunity Announcement (FOA) invites applications from the two previously funded Rare and Atypical DIAbetes NeTwork (RADIANT) research centers to further study rare and atypical forms of diabetes mellitus. These centers will continue to identify and analyze phenotypic and genotypic defects that may provide insights into more common, heterogeneous forms of diabetes mellitus in the general population. RADIANT will also continue to develop community resources to advance research in this area through the collection and dissemination of data and samples for access by the broad research community. During this grant cycle, RADIANT will establish precision diagnoses for new Mendelian forms of diabetes by enrolling family members of previously enrolled participants with a family history suggestive of a Mendelian form of diabetes to aid in identifying potential causal variants. In addition, in vitro and basic studies leveraging induced pleuripotent stem cells (iPSCs) differentiated into tissues of interest will be used to establish pathogenicity of potential causal variants.

## Questions people ask

### Is RFA-DK-22-511 still open?

No. It closed on June 7, 2023.

### Who can apply for Limited Competition for the Continuation of the Rare and Atypical Diabetes NeTwork (RADIANT) Specialized Study Centers (U54 - Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Limited Competition for the Continuation of the Rare and Atypical Diabetes NeTwork (RADIANT) Specialized Study Centers (U54 - Clinical Trial Not Allowed)?

Closed June 7, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-DK-22-511?

NIH RePORTER lists 2 projects funded under RFA-DK-22-511 in fiscal 2024 to 2026, at 2 institutions. The most were at University of Chicago, Baylor College of Medicine.

### Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.